semaglutide
Secret Semaglutide Exclusion Swings Small Pharmacies
Secret Semaglutide Exclusion Swings Small Pharmacies The FDA’s decision to remove semaglutide and tirzepatide from the 503B bulk list will raise sourcing costs for small compounding pharmacies, potentially limiting patient access to affordable GLP-1 weight-loss therapies. Discover how a single regulatory tweak could trigger a domino effect, driving up